Eli Lilly Shares Bought by Grantham Mayo Van Otterloo & Co. LLC

Institutional investor increases stake in pharmaceutical giant by nearly 50%

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Grantham Mayo Van Otterloo & Co. LLC, a major institutional investor, increased its holdings in Eli Lilly and Company (NYSE: LLY) by 47.8% in the third quarter of 2026. The firm now owns 700,608 shares of the pharmaceutical company's stock, making it one of Eli Lilly's larger shareholders.

Why it matters

Eli Lilly is one of the world's leading pharmaceutical companies, with a diverse portfolio of drugs and therapies. Institutional investors like Grantham Mayo Van Otterloo closely follow and invest in major pharmaceutical stocks, as their performance can significantly impact the broader market.

The details

According to a recent SEC filing, Grantham Mayo Van Otterloo & Co. LLC increased its stake in Eli Lilly by adding 226,586 shares during the third quarter of 2026. This brings the firm's total holdings in Eli Lilly to 700,608 shares, or approximately 0.07% of the company's outstanding stock. Grantham Mayo Van Otterloo & Co. LLC cited Eli Lilly's strong product pipeline and growth potential as reasons for the increased investment.

  • Grantham Mayo Van Otterloo & Co. LLC increased its Eli Lilly holdings in the third quarter of 2026.

The players

Grantham Mayo Van Otterloo & Co. LLC

A major institutional investment firm that manages over $500 billion in assets.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana.

Got photos? Submit your photos here. ›

The takeaway

Eli Lilly's continued success and growth potential have attracted the attention of top institutional investors like Grantham Mayo Van Otterloo, further solidifying the company's position as a leading player in the pharmaceutical industry.